BSX · 10-Q · 2026Q2 · Full report
Liquidity and Cash Position
BOSTON SCIENTIFIC CORP · 2026-08-03 · Importance 64 · Surprise 42 · In source text
Boston Scientific held $539 million of unrestricted cash and cash equivalents at June 30, 2026, including $130 million in money-market funds and time deposits and $409 million in bank accounts. The company entered a new $3.0 billion revolving credit agreement maturing February 26, 2031, with $1.689 billion of commercial paper outstanding and $1.311 billion of additional availability. A separate $2.0 billion 364-day revolver and $6.0 billion term-loan facility were undrawn and available only in connection with the Penumbra acquisition. The company reported a 2.02 times actual leverage ratio versus a 4.00 times permitted maximum and remained compliant with its financial covenant.
Key facts
- On February 26, 2026, Boston Scientific entered into a $2.000 billion 364-day revolving credit agreement and a $6.000 billion term loan credit agreement that permit up to a $1.000 billion Tranche A Loan and up to a $5.000 billion Tranche B Loan, each drawable only upon closing of the pending Penumbra acquisition and maturing 364 days thereafter. source
- As of June 30, 2026, there was $1.689 billion outstanding under the commercial paper program and no amounts outstanding under the 2026 Revolving Credit Agreement, resulting in an additional $1.311 billion of available liquidity under that agreement. source
- On February 26, 2026, Boston Scientific entered into a new $3.000 billion revolving credit agreement (the 2026 Revolving Credit Agreement) that matures on February 26, 2031, with one-year extension options subject to certain conditions. source
- As of June 30, 2026, Boston Scientific had $539 million of unrestricted cash and cash equivalents on hand, comprised of $130 million invested in money market funds and time deposits and $409 million in bank accounts. source
- As of June 30, 2026, Boston Scientific had no amounts outstanding under the 364-Day Revolving Credit Agreement or Term Loan Credit Agreement. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | realized | — | As of June 30, 2026, there was $1.689 billion outstanding under the commercial paper program and no amounts outstanding under the 2026… |